BlessUp Peptide Library · Energy & Longevity
MOTS-c, Humanin, and SS-31. Three peptides aimed at the cell's power plant, with wildly different amounts of proof.
Two send a signal. One repairs the hardware. Only one has real human trials, and even those are mixed.
SS-31 (elamipretide) is FDA-approved for one rare disease and has real trials, but its largest myopathy trial missed its primary endpoints. MOTS-c and Humanin have compelling biology and little-to-no human outcome data. Full citations at the end.
You have seen them sold as the same idea: MOTS-c, Humanin, and SS-31, a set of peptides that all promise to fix your mitochondria, the tiny power plants inside every cell that turn food and oxygen into usable energy.
Here is the honest version. These three do not do the same job, and they are not backed by the same proof. Two of them (MOTS-c and Humanin) are mitochondrial-derived peptides, tiny signals your own mitochondria actually make, that decline as you age. They are messengers: MOTS-c tunes your metabolism, Humanin protects stressed cells from dying. The third, SS-31, is a synthetic peptide that does something different entirely, it physically stabilizes the inner membrane where energy is made. And it is the only one of the three with real human clinical trials behind it. The catch is that those trials have been mostly disappointing. So the useful thing we can do is line each one up against what it actually does and the proof it actually has. We do honest, not hype.
Read this first
This is education, not medical advice, and it does not replace your own clinician. Of this class, only SS-31 (elamipretide) is an approved medicine, and only for one rare condition (Barth syndrome); every other use is off-label and investigational. MOTS-c and Humanin are research compounds with no completed human dosing trials. Any dose named here is an example for discussion, never a prescription.
90-second self-check
This flags the real hard stops, and if you are clear, points toward the compound that matches your goal. It is education, not a diagnosis or a recommendation to use anything.
Answer honestly. Nothing is stored, and no one sees it but you.
First, the hard stops. Do any of these apply to you? (tap all that are true)
What are you actually weighing this class for?
Any of these in your picture? (tap all that apply)
Is the real energy foundation in place? (tap all that apply)
This reflection is education only, not a diagnosis or a recommendation to use any compound. Talk to a licensed provider about your own history and goals.
The basics
Your mitochondria are the power plants inside your cells: they take food and oxygen and produce ATP, the fuel that runs everything you do. As you age, mitochondria get fewer, leakier, and less efficient, which is a genuine part of why energy and resilience fade. All three of these peptides aim at that decline, but from very different angles:
| Compound | What it does to the mitochondria | Studied for | Evidence level | Route |
|---|---|---|---|---|
| MOTS-c | Signals: switches on AMPK (an exercise / fasting mimic) | Insulin sensitivity, fat burning, endurance | Strong animal data; no human dosing trials | SubQ |
| Humanin | Signals: protects stressed cells from dying (anti-apoptotic) | Neuroprotection, cellular resilience, longevity | Mechanism plus human association; no efficacy trials | SubQ |
| SS-31 / elamipretide | Repairs: stabilizes cardiolipin, holds the membrane together | Mitochondrial myopathy, heart, eye disease | 700+ patients, FDA-approved (Barth); trials mixed | SubQ / IV |
One name to keep straight: SS-31 goes by several labels, elamipretide, MTP-131, and the older research name Bendavia. They are the same molecule. And "mitochondrial peptides" here means these three specifically, not NAD+ boosters like NMN or NR, which chase a different mitochondrial problem and are covered in our longevity and senolytics guide.
The honest half-truth you will hear
"They fix your mitochondria." That flattens three very different stories into one. MOTS-c sends a metabolic signal, Humanin sends a survival signal, and only SS-31 physically repairs anything. More importantly, "fix" implies proven results in people. For the two natural peptides there are essentially no human outcome trials, and for the synthetic one the biggest trial was disappointing. The mechanisms are elegant. Proven benefit is a separate thing.
The part the marketing flattens
They get sold on the same shelf as if the evidence were equal. It is not. Here is an honest read of how much real human data sits behind each. Longer bars mean deeper human evidence, not "works better," and even the longest bar comes with a heavy asterisk.
Depth of human evidence, by compound
SS-31 has by far the most human data, and its biggest trial still missed its primary endpoint. The two natural peptides are mechanism and biomarkers.
SS-31: MMPOWER-2 (Karaa 2020) showed a signal but missed its primary walking endpoint, and the larger Phase 3 (MMPOWER-3) missed its primary endpoints. MOTS-c: the discovery and metabolic work is preclinical (Lee 2015). Humanin: human data is associative. Full citations below.
Read the shape honestly. Even the compound with the deepest record, SS-31, has a mixed clinical track record, and its FDA approval covers only one rare disease. The two natural peptides are earlier still, exciting biology waiting on human outcome trials that have not been done. If you are drawn to this class, go in knowing the proof is thinner than the promise.
Under the hood
MOTS-c flips on AMPK, your cell's master energy switch, the same one exercise and fasting trigger. That pushes muscle to burn fuel more efficiently. It is a signal that fades fast but whose effect on your metabolism lingers for a day or two.
Humanin blocks the internal "self-destruct" step (it neutralizes a protein called BAX) and flips on survival signaling. It does not add energy, it keeps a stressed cell, especially a neuron, from tipping over into death.
SS-31 concentrates in the inner membrane and clamps onto cardiolipin, the fat that keeps the energy-producing machinery lined up. That preserves structure and cuts the leak of damaging free radicals at the source, rather than mopping them up after.
That is the whole class in three sentences: a metabolic signal, a survival signal, and a structural repair. It is why they do not really compete, and also why "stack them all" is a marketing idea, not an evidence-based one. Each is aimed at a different problem, and each carries a different (mostly unproven) level of support.
The three, with honest pros and cons
Same target organelle, very different levels of proof. Tags show the standing: clinical, emerging, or preclinical.
A synthetic peptide that stabilizes cardiolipin in the inner membrane. The only member with real human trials and an FDA approval, and the only one whose disappointing results we can actually see.
Honest read: the proven mechanism and the only real trials, but a mixed clinical scorecard. A provider-supervised, mechanism-first tool, not a sure thing. Given by injection or IV.
A natural mitochondrial peptide that switches on AMPK, the same energy sensor exercise triggers. Exciting metabolic biology, with the human dosing evidence still missing.
Honest read: the most promising metabolic story, but human translation is still an assumption, not a result. Best paired with actual training. Given by subcutaneous injection.
The first mitochondrial-derived peptide discovered, a cell-protection signal. The most speculative of the three, strong on mechanism, thin on human proof.
Honest read: fascinating longevity biology, run it like a careful experiment, not a protocol. Cancer history is a real caution here. Given by subcutaneous injection.
The line that matters most
The single most important idea in this class is the gap between mechanism and outcome. Every one of these three has genuinely elegant biology, and mitochondrial decline is a real hallmark of aging, so the target is legitimate. But in humans, that is where it mostly stops. SS-31 has real trials and a mixed record. MOTS-c and Humanin have almost no human outcome data at all. Raising a lab value, activating a pathway, or protecting a cell in a dish is step one of a very long road to "this makes people healthier."
Two things to hold onto
First, these do not compete, so "stack all three" is a sales idea, not an evidence-based plan, each is aimed at a different piece with a different (mostly thin) level of proof. Second, the compound with the most human study, SS-31, is also the one whose disappointments we can actually see. That honesty cuts both ways: it is the most proven mechanism and the most clearly mixed results. Go in with clear eyes.
The most important section here
These are generally well tolerated, but a few situations are genuinely off-limits or need a provider, and the reasons come straight from the mechanisms.
This is the sharpest caution, and it is strongest for Humanin. Humanin is a pro-survival, anti-death signal, and resisting cell death is exactly what cancer cells do, so pushing that signal is theoretically the wrong direction. MOTS-c's AMPK pathway also intersects with cancer metabolism in complicated ways. This is a mechanistic concern, not a documented harm, but it is a firm reason to stop and clear it with an oncologist.
None of the three has human safety data in pregnancy or breastfeeding. Do not use if you are pregnant, breastfeeding, or trying to conceive. Clear that first.
MOTS-c activates AMPK, the same pathway metformin works through, and it can lower blood sugar. Combined with metformin, insulin, or a GLP-1 drug, that risks pushing blood sugar too low. If you take any of those, this is a provider conversation, not a solo stack.
SS-31 is cleared mainly by the kidneys. If your kidney function is reduced, or you take kidney-stressing drugs (certain antibiotics, chronic high-dose anti-inflammatories), that raises the load. Kidney function is the thing to monitor with this one.
MOTS-c and Humanin are research compounds with no approval and thin safety data, treat them as experimental. And MOTS-c is banned by the World Anti-Doping Agency (metabolic modulator class), so it is off-limits for drug-tested athletes.
The one rule under all of it
If you have an active cancer history, this class (Humanin especially) is not a self-directed project, clear it with an oncologist first. Otherwise, match the compound to a real goal, respect the drug interactions, and build the energy foundation below first, because for most people it does more than any of these.
Put it together
First question
Second question
The move most people skip
Ask what specific problem you are solving. "Better mitochondria" is not a target, insulin sensitivity, endurance, recovery, or cellular protection are. Match the tool to the real goal, respect that the human proof is thin, and keep a provider in the loop. Matching beats maxing.
The foundation under everything
Here is the part no peptide wants you to hear: the single most powerful mitochondrial intervention known is free, and it is exercise. These peptides at best nudge on top of a foundation. Without it, there is far less for them to do.
Endurance work (steady zone-two cardio) plus resistance training is what actually builds new mitochondria and improves the ones you have. MOTS-c literally mimics the exercise signal, which is exactly why the best responders are people already training. There is no version of this where the injection replaces the work.
Mitochondria repair and clear out damaged parts during sleep. Short or broken sleep measurably degrades energy metabolism. No peptide compensates for chronic sleep debt. Fix this first.
A protein-adequate, whole-food diet and a healthy weight keep mitochondria efficient; chronic overfeeding and excess fat make them leak. Periods of genuine hunger (a real fast or a lower-carb window) also flip on the same AMPK pathway MOTS-c targets, for free.
Sauna and cold exposure are mild mitochondrial stressors that prompt adaptation, and smoking directly poisons the machinery. These are ordinary, evidence-aligned levers that dwarf what any of these peptides has been shown to do in people.
Cutting through the noise
The genuinely evidence-backed way to build and protect mitochondria. This does more than any peptide in this class. Boring, and it works.
The one member with a proven mechanism and real trials, worth a measured, monitored trial with a defined endpoint, with the honest caveat that its clinical record is mixed. Not a casual purchase.
Compelling biology, but no completed human dosing trials. Curiosity and a careful experiment, not confidence, and MOTS-c only really earns its keep alongside training.
The exact situation where a pro-survival or pro-growth signal can push the wrong way. This is a specialist decision, never a self-directed one.
Turn this into action
Have I honestly ruled out the hard stops: active or recent cancer, and pregnancy?
What specific problem am I actually solving, metabolism, endurance, protection, or just "energy" in the abstract?
Am I already training, sleeping, and eating in a way that gives a mitochondrial peptide something to work with?
If I take a glucose-lowering drug or have kidney issues, have I accounted for the interaction?
Am I clear that the human proof here is thin, and is a provider genuinely involved?
Bring these to your visit
Given my history, especially any cancer, is any mitochondrial peptide safe for me to consider?
If I take metformin, insulin, or a GLP-1, how would MOTS-c affect my blood sugar?
Should we check kidney function before and during anything like SS-31?
Given how thin the human evidence is, what realistic result should I even expect, and when would we call it and stop?
A few situations are not "go slower," they are "stop and be seen."
A mild injection-site reaction settles. A hypoglycemic episode, a kidney warning sign, or an allergic reaction do not wait. When in doubt, be seen.
The BlessUp take
The idea here is genuinely beautiful: your mitochondria are the furnace of every cell, they fade with age, and these three peptides each grab a different lever, MOTS-c the metabolic signal, Humanin the survival signal, SS-31 the structural repair. But two honest truths run underneath the marketing. First, they do not do the same job, so "stack all three for mitochondrial health" is a sales pitch, not a plan, each targets a different piece with a different level of support. Second, and this is the big one, the proof is thinner than the promise. The two natural peptides have almost no human outcome trials at all. The one synthetic peptide with real trials, SS-31, has a mixed-to-disappointing record and an FDA approval for exactly one rare disease. So enjoy the elegant biology, but do not confuse it with a result. For most people, the most powerful thing you can do for your mitochondria is not an injection, it is training, sleep, and hunger, the very signals MOTS-c is trying to imitate. If you do have a real reason and a clear head, favor the mechanism you can actually monitor, watch the cancer and blood-sugar and kidney lines, and do it with a provider. That is not the timid move. It is the one that respects how little we still know.
The evidence
Retrieved from PubMed. SS-31 (elamipretide) carries the class's real clinical evidence, shown here as both a signal (MMPOWER-2) and a missed primary endpoint (MMPOWER-2 walking test), with the larger Phase 3 also missing its primary endpoints. MOTS-c and Humanin rest on preclinical and associative data.
Citations retrieved from PubMed. SS-31's strong human record is in specific diseases (and its largest myopathy trial, MMPOWER-3, missed its primary endpoints, with benefit only in a genetic subgroup). MOTS-c has robust animal data but no completed human dosing trials; Humanin's human evidence is associative, higher natural levels track with longevity, without efficacy trials of supplementing it. This report is an honest educational map of the class, not a dosing sheet or a recommendation to use any compound.